Clinical-stage pharmaceutical and drug delivery device company developing and commercializing the proprietary use & delivery of XENEX™ (xenon) inhalation gas, to protect against brain cell death following acute neurologic injury
Xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results1 and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes (Results published in JAMA -Journal of the American Medical Association-, March 2016)
Value Provided by Frontcourt
Engaged to raise Series B Funding Round to continue latestage Phase III clinical development and explore all potential options
Conducted thorough due diligence including attending key industry events to identify company awareness and develop our strategy
Identified our target strategy of running a parallel process of capital raise efforts alongside exploring strategic alternatives
Created investor and M&A Overview presentations
Identified interested investors for a $40M Series B Round
Identified strategic buyers with interest in Drug Device and Neurology
Presented multiple options and ultimate recommendation to management and the Company
Facilitated successful US license of NeuroproteXeon by Mallinckrodt plc (NYSE:MNK)
